The IMPACT Trial: Single Inhaler Triple Therapy vs dual therapies: Efficacy across multiple COPD endpoints over timedoi:10.1183/13993003.congress-2019.PA2482COPD - managementBackground: IMPACT is a randomized, multicenter study (52 weeks) comparing the efficacy and safety of fluticasone furoate/...
Patients with chronic obstructive pulmonary disease (COPD) prefer Respimat® Soft MistTM Inhaler over traditional devicesContact:Boehringer Ingelheim GmbHCorporate Division Communications Judith von Gordon55216 Ingelheim am RheinGERMANYPhone: +49/6132/77 35 82Fax: +49/6132/77 66...
The extent to which this co-administration occurs in clinical practice has not been well studied to date.Methods: We assessed records of patients admitted to Oxford University Hospitals NHS in the last 6 months with primary diagnosis of acute COPD exacerbation, on a triple combination inhaler. ...